

UNITED STATES OF AMERICA
Before the
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Administrative Proceedings Rulings
Release No. 5341 / December 8, 2017

Administrative Proceeding
File No. 3-18141

In the Matter of

**CellCyte Genetics Corp.,
China Pediatric
Pharmaceuticals, Inc., and
Hawker Energy, Inc.**

**Order Regarding
the Securities and Exchange
Commission's Order on Pending
Administrative Proceedings**

On August 28, 2017, the Securities and Exchange Commission issued an order instituting proceedings (OIP) pursuant to Section 12(j) of the Securities Exchange Act of 1934, alleging that Respondents have securities registered with the Commission under Section 12(g) of the Exchange Act and are delinquent in their periodic filings. On September 14, 2017, the Commission accepted an offer of settlement from Respondent Hawker Energy, Inc. *CellCyte Genetics Corp.*, Exchange Act Release No. 81621, 2017 SEC LEXIS 2865. On October 10, 2017, I issued an initial decision revoking the registrations of each class of registered securities of CellCyte Genetics Corp. *CellCyte Genetics Corp.*, Initial Decision Release No. 1184, 2017 SEC LEXIS 3237. Respondent China Pediatric Pharmaceuticals, Inc., has not yet been served with the OIP.

On November 30, 2017, the Commission issued an order directing all administrative law judges with pending proceedings to: (1) reconsider the record in the proceeding, including all substantive and procedural rulings; (2) allow the parties to file any new evidence that the parties deem relevant to the reexamination of the record by January 5, 2018; (3) determine whether to revise or ratify prior rulings; and (4) issue by February 16, 2018, an order on ratification. *Pending Admin. Proc.*, Securities Act of 1933 Release No. 10440, 2017 SEC LEXIS 3724, <https://www.sec.gov/litigation/opinions/2017/33-10440.pdf>.

Accordingly, I ORDER CellCyte Genetics and the Division of Enforcement to file by January 5, 2018, any new evidence that they consider relevant to my reexamination of the record in this proceeding. Each party may also submit a brief explaining the relevance of its new evidence and identifying any challenged rulings, findings, or conclusions. If either party chooses to submit a brief by January 5, the other party will have until January 16, 2018, to file a responsive brief.

I will enter a schedule providing China Pediatric with a similar opportunity to submit new evidence relevant to my reexamination of the record once it has been served. *See Pending Admin. Proc.*, 2017 SEC LEXIS 3724, at *3-4 (allowing the administrative law judge to modify deadlines in the Commission's order for good cause).

Brenda P. Murray
Chief Administrative Law Judge